We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Polydex Pharmaceuticals Ltd (PK) | USOTC:POLXF | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.986 | 1.98 | 2.00 | 0.00 | 01:00:00 |
Q.1, ending 4/30/2011 | Q.1, ending 4/30/2010 | |
Sales | $1,730,838 | $1,293,329 |
Net Income | 147,134 | (83,136) |
Income (loss) per common share | 0.05 | (0.03) |
Weighted avg. common Shares outstanding (basic and diluted) | 3,122,846 | 3,072,846 |
The company's long-standing reputation for consistent high-grade product has generated increasing interest in the company's core product line from both new and existing customers on a worldwide basis, resulting in an increased level of orders.
"It's great to see a return to profitability," says George Usher, President and CEO. "The plant is operating around the clock during the week, and our customers continue to indicate their needs for more product. We intend to remain vigilant with our quality-control and cost-management efforts, in order to produce the highest quality products needed to meet our customers' demands. Our continued efforts to increase profit margins and sales should help to meet our goal of increasing shareholder value."
The Company shares are traded on the Over the Counter Bulletin Board (www.otcbb.com). The company continues full disclosure of its financial and operational results, which can be accessed by visiting the company website at www.Polydex.com. Product information is available at www.dextran.ca
Polydex Pharmaceuticals Limited, based in Toronto, Ontario, Canada, is engaged in the development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market, and also manufactures bulk pharmaceutical intermediates for the worldwide veterinary pharmaceutical industry.
The Polydex Pharmaceuticals Limited logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3414
Note: This press release may contain forward-looking statements, within the meaning of the United States Securities Act of 1933, as amended, and the United States Securities Exchange Act of 1934, as amended, regarding Polydex Pharmaceuticals Limited, including, without limitation, statements regarding expectations about future revenues or business opportunities or potential research projects. These statements are typically identified by use of words like "may", "could", "might", "expect", "anticipate", "believe", or similar words. Actual events or results may differ materially from the Company's expectations, which are subject to a number of known and unknown risks and uncertainties including but not limited to changing market conditions, future actions by the United States Food and Drug Administration or equivalent foreign regulatory authorities as results of pending or future clinical trials. Other risk factors discussed in the Company's filings with the United States Securities and Exchange Commission may also affect the actual results achieved by the Company.
CONTACT: Investor Relations: North Arm Capital Services Linda Hughes 1-877-945-1621 (Linda@northarm.com)
1 Year Polydex Pharmaceuticals (PK) Chart |
1 Month Polydex Pharmaceuticals (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions